^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Mvasi (bevacizumab-awwb)

    i
    Other names: ABP 215
    Company:
    AbbVie, Amgen, Daiichi Sankyo
    Drug class:
    VEGF-A inhibitor
    Related drugs:
    2ms
    CodeBreaK 301: Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (clinicaltrials.gov)
    P3, N=450, Not yet recruiting, Amgen
    New P3 trial • Metastases
    |
    Avastin (bevacizumab) • 5-fluorouracil • Vectibix (panitumumab) • Lumakras (sotorasib) • irinotecan • leucovorin calcium • Mvasi (bevacizumab-awwb)
    6ms
    A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, Criterium, Inc. | N=43 --> 0 | Trial completion date: Jun 2028 --> Jan 2023 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2026 --> Jan 2023
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date • Combination therapy • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Lumakras (sotorasib) • Mvasi (bevacizumab-awwb)
    10ms
    Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb). (PubMed, Ther Adv Med Oncol)
    None of the EOIs resulted in death. In this real-world cohort of mCRC patients who were treated 1L with a bevacizumab biosimilar (bevacizumab-awwb), the clinical effectiveness and tolerability data were as expected and consistent with previously published findings from real-world studies of bevacizumab RP in mCRC patients.
    Journal • Real-world evidence • Real-world • Metastases
    |
    Mvasi (bevacizumab-awwb)
    almost2years
    A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis (clinicaltrials.gov)
    P1/2, N=43, Recruiting, Criterium, Inc. | Not yet recruiting --> Recruiting | Initiation date: Mar 2022 --> Jun 2022
    Enrollment open • Trial initiation date • Combination therapy
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Lumakras (sotorasib) • Mvasi (bevacizumab-awwb)
    over2years
    A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis (clinicaltrials.gov)
    P1/2, N=43, Not yet recruiting, Criterium, Inc.
    New P1/2 trial • Combination therapy
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Lumakras (sotorasib) • Mvasi (bevacizumab-awwb)
    over2years
    A phase 1b study of sotorasib, a specific and irreversible KRASG12C inhibitor, in combination with other anticancer therapies in advanced colorectal cancer (CRC) and other solid tumors (CodeBreaK 101). (ASCO-GI 2022)
    Key regimens being explored in CRC include (1) Subprotocol A: Sotorasib + trametinib (MEK inhibitor) +/- panitumumab (EGFR inhibitor), (2) Subprotocol H: Sotorasib + panitumumab and sotorasib + panitumumab + FOLFIRI, and (3) Subprotocol M: Sotorasib + bevacizumab-awwb + FOLFIRI or FOLFOX. Contact Amgen Medical Information for more information: medinfo@amgen.com (NCT04185883). Abbreviations: EGFR = epidermal growth factor receptor; FOLFIRI = 5-fluorouracil + leucovorin + irinotecan; FOLFOX = 5-fluorouracil + leucovorin + oxaliplatin; MEK = mitogen-activated protein kinase.
    P1 data • Combination therapy
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C
    |
    Avastin (bevacizumab) • Mekinist (trametinib) • 5-fluorouracil • Vectibix (panitumumab) • Lumakras (sotorasib) • oxaliplatin • irinotecan • leucovorin calcium • Mvasi (bevacizumab-awwb)
    3years
    Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    No abstract available
    Clinical • New P2 trial
    |
    ALB (Albumin)
    |
    Avastin (bevacizumab) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zirabev (bevacizumab-bvzr) • Onivyde (nanoliposomal irinotecan) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)
    over3years
    Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, M.D. Anderson Cancer Center
    Clinical • New P2 trial
    |
    ALB (Albumin)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zirabev (bevacizumab-bvzr) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)
    over3years
    A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma (clinicaltrials.gov)
    P2; N=30; Recruiting; Sponsor: Elizabeth Buchbinder; Not yet recruiting --> Recruiting; Trial primary completion date: Sep 2020 --> Sep 2022
    Trial primary completion date • Enrollment open
    |
    ALB (Albumin)
    |
    PD-L1 negative • TILs
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Mvasi (bevacizumab-awwb)
    almost4years
    Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Participants With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P2; N=96; Recruiting; Sponsor: National Cancer Institute (NCI); Trial completion date: Jun 2020 --> Jun 2021; Trial primary completion date: Jun 2020 --> Jun 2021
    Trial completion date • Trial primary completion date • Clinical
    |
    MSLN (Mesothelin)
    |
    MSLN positive
    |
    Oncomine™ Dx Target Test
    |
    Avastin (bevacizumab) • paclitaxel • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • anetumab ravtansine (BAY 94-9343) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)
    almost4years
    [VIRTUAL] Demographics and clinical characteristics of metastatic colorectal cancer patients treated with a biosimilar to bevacizumab (ESMO-GI 2020)
    Background Bevacizumab-awwb, a biosimilar to bevacizumab, is the first therapeutic biosimilar to receive FDA approval for the treatment of metastatic colorectal cancer (mCRC) with intravenous 5-FU-based chemotherapy for first-line or second-line treatment, as well as for use in treatment regimens for first-line non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, and metastatic cervical cancer...Legal entity responsible for the study Amgen Inc., Thousand Oaks, CA. Funding This study is funded by Amgen, Inc., Thousand Oaks, CA.
    Clinical • MSi-H Biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    MSI-H/dMMR
    |
    Mvasi (bevacizumab-awwb)
    4years
    A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma (clinicaltrials.gov)
    P2; N=30; Not yet recruiting; Sponsor: Elizabeth Buchbinder
    New P2 trial
    |
    ALB (Albumin)
    |
    PD-L1 negative • TILs
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Mvasi (bevacizumab-awwb)